Sponsors

Lead Sponsor

CloudCath

This study will evaluate the safety and effectiveness of the CloudCath System to detect the onset of peritonitis as compared to standard of care. Study Participants will connect the CloudCath System to their home peritoneal dialysis unit and the CloudCath System will analyze the effluent dialysis solution for changes associated with peritonitis. The notification capability of the CloudCath System will be deactivated for this study so that neither Study Participants nor Study Investigators will be aware of the device measurements. Following enrollment, Study Participants will use the CloudCath System for 12 continuous months.

Related studies

RECRUITINGPhase 4

Pharmacokinetics of Intraperitoneal and Intravenous Meropenem, Ampicillin, Aztreonam and Ciprofloxacin in Automated Peritoneal Dialysis Patients Without Peritonitis

NCT07113587 · Peritoneal Dialysis-associated Peritonitis, Peritoneal Dialysis (PD), and more

SUSPENDED

In Vitro Analysis of Effluent Dialysate Solution From Patients on Peritoneal Dialysis, With the CloudCath Device

NCT05300191 · Peritoneal Dialysis-associated Peritonitis, End Stage Renal Disease

View all related studies →

A Prospective Clinical Study of the CloudCath System During In-home Peritoneal Dialysis

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Oral Vitamin D Supplementation Prevent Peritoneal Dialysis-related Peritonitis

Clinical Trial on Antibiotic-Lock in Tenckhoff Catheter for Relasping and Repeat Peritonitis

Prevention of Peritonitis in Peritoneal Dialysis

Pharmacokinetics of Intraperitoneal and Intravenous Meropenem, Ampicillin, Aztreonam and Ciprofloxacin in Automated Peritoneal Dialysis Patients Without Peritonitis

In Vitro Analysis of Effluent Dialysate Solution From Patients on Peritoneal Dialysis, With the CloudCath Device

Trial snapshot

Condition

Locations shown

For caregivers